STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLGN
  4. [Form 3] CollPlant Biotechnologies Ltd Initial Statement of Beneficial Ownership

CollPlant Biotechnologies (CLGN) director details option and RSU stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

CollPlant Biotechnologies director Avraham Havron has filed an initial statement of beneficial ownership, detailing his equity-based awards in the company. The filing reports options over 4,000 ordinary shares at an exercise price of $4.02 per share, expiring on January 14, 2028, which are fully vested and exercisable. It also reports options over 8,000 ordinary shares at $6.39 per share expiring on August 27, 2030, and options over 24,000 ordinary shares at $6.39 per share expiring on May 2, 2032, of which 22,500 are currently vested and the remaining 1,500 vest on May 2, 2026 subject to continued service. In addition, he holds 10,000 restricted share units, with 3,125 already vested and 6,875 scheduled to vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, contingent on ongoing service.

Positive

  • None.

Negative

  • None.
Insider Havron Avraham
Role Director
Type Security Shares Price Value
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
holding Restricted Share Units -- -- --
Holdings After Transaction: Options to Purchase Ordinary Shares — 4,000 shares (Direct); Restricted Share Units — 10,000 shares (Direct)
Footnotes (1)
  1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's Share Ownership and Option Plan (2010) or 2024 Share Award Plan must be registered in the name of a trustee. Of the restricted share units reported herein, 3,125 units are vested, and the remaining 6,875 units vest in eleven equal quarterly installments beginning March 25, 2026 and ending September 25, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date. Fully vested and exercisable. 22,500 options are fully vested and exercisable and the remaining 1,500 vest is May 2, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Havron Avraham
(Last)(First)(Middle)
C/O COLLPLANT BIOTECHNOLOGIES LTD.
4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK
(Street)
REHOVOT7670104
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
CollPlant Biotechnologies Ltd [ CLGN ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Share Units(1)10,000(2)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Options to Purchase Ordinary Shares(1)(3)01/14/201901/14/2028Ordinary Shares4,000(3)$4.02D
Options to Purchase Ordinary Shares(1)(3)08/27/202108/27/2030Ordinary Shares8,000(3)$6.39D
Options to Purchase Ordinary Shares(1)(4)05/02/202305/02/2032Ordinary Shares24,000(4)$6.39D
Explanation of Responses:
1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's Share Ownership and Option Plan (2010) or 2024 Share Award Plan must be registered in the name of a trustee.
2. Of the restricted share units reported herein, 3,125 units are vested, and the remaining 6,875 units vest in eleven equal quarterly installments beginning March 25, 2026 and ending September 25, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
3. Fully vested and exercisable.
4. 22,500 options are fully vested and exercisable and the remaining 1,500 vest is May 2, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
/s/ Avraham Havron03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the CollPlant (CLGN) Form 3 filing by Avraham Havron show?

The Form 3 shows Avraham Havron’s existing equity-based holdings in CollPlant. It details his stock options and restricted share units, including exercise prices, expiration dates and vesting schedules, providing a baseline of his current compensation-linked stake as a company director.

How many stock options does Avraham Havron hold in CollPlant (CLGN)?

Avraham Havron holds options tied to 36,000 CollPlant ordinary shares. These include 4,000 options at $4.02 per share expiring in 2028, plus 8,000 and 24,000 options at $6.39 per share expiring in 2030 and 2032, with most already vested.

What restricted share units are reported for Avraham Havron at CollPlant (CLGN)?

The filing reports 10,000 restricted share units for Avraham Havron. Of these, 3,125 units are vested, while 6,875 will vest in eleven equal quarterly installments between March 25, 2026 and September 25, 2028, assuming his continued service with the company.

Are Avraham Havron’s CollPlant (CLGN) options currently exercisable?

Most of Avraham Havron’s options are already vested and exercisable. All 4,000 options at $4.02 are fully vested, and 22,500 of the 24,000 options at $6.39 are vested, with the remaining 1,500 vesting on May 2, 2026 subject to continued service.

Does the CollPlant (CLGN) Form 3 indicate any recent insider buying or selling?

No recent insider buying or selling is indicated in this Form 3. The document functions as an initial ownership statement, listing Havron’s existing options and restricted share units rather than reporting new market transactions or changes in his overall position.

What are the vesting conditions on Avraham Havron’s CollPlant (CLGN) equity awards?

Vesting of Havron’s equity awards depends on his continued service to CollPlant. Certain options vest by May 2, 2026, while 6,875 restricted share units vest in eleven quarterly installments through September 25, 2028, provided he remains with the company on each vesting date.